SynthesisScientific reports2025

Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.

Ameen S S Alwashmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.